StockNews.AI
BMY
StockNews.AI
144 days

Bristol Myers Squibb Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo for Resectable Non-Small Cell Lung Cancer in Patients with Tumor Cell PD-L1

1. BMY received positive CHMP opinion for Opdivo's perioperative regimen. 2. This could enhance sales potential and market position for BMY.

2m saved
Insight
Article

FAQ

Why Bullish?

The positive CHMP opinion indicates potential for increased sales and market share. Similar past approvals often led to stock price increases, as seen with other drugs gaining positive regulatory feedback.

How important is it?

The positive regulatory opinion is likely to significantly influence BMY’s market performance and investor sentiment due to the therapeutic potential of Opdivo.

Why Long Term?

Successful implementation of the treatment regimen could take time to reflect in sales figures. Historical product approvals, such as with immunotherapy agents, show long-term revenue growth post-approval.

Related Companies

OPDUJNJAMGN
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CHMP--BMS Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo and Chemotherapy Followed by Surgery and Adjuvant Opdivo.

Related News